Hallucinogenic drug research--if so, so what? Symposium summary and commentary.
D X Freedman
Pharmacology, Biochemistry, and Behavior February 1986 DOI: 10.1016/0091-3057(86)90371-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Conference report Peer reviewed |
|---|---|
| Key points | The report argues that pharmacokinetic evidence and critique no longer support the presynaptic-disinhibition model of LSD effects or the description of LSD-induced "slowed turnover" of serotonin, and that subcellular compartment analyses require major revision of how cytoplasmic and vesicular amine ratios and intraneuronal MAO accessibility are understood. It also identifies sensitizing effects of mescaline and LSD, drug discrimination tests, and fixed-ratio operant schedules as promising research directions. |
Abstract
The conference brought a critical focus both on older findings and new strategies in hallucinogenic drug research as well as on behavioral and electrophysiologic tools that correlate with neurobehavioral and neurochemical events. A number of unsolved problems to be investigated were noted. The sensitizing effects of both mescaline and LSD on other inputs at motor nuclei or at limbic sites, and effects on afferent processes were examples of important new directions as were drug discrimination tests that can determine the relative roles of aminergic systems in drug effect. Fixed ratio operant schedules can differentiate serotonin blocking agents, detect active indole psychotomimetics and demonstrate temporal and tolerance parameters relevant to drug induced neurochemical changes. Data and critique as well as pharmacokinetics no longer support the presynaptic-disinhibition model of LSD effects, nor is LSD induced "slowed turnover" of serotonin seen as an accurate description of neurochemical changes. The distinct nerve ending biochemical changes after LSD are reviewed. Subcellular compartmental analyses require a radical revision of the picture of the ratio in the nerve ending of cytoplasmic and vesicular amine as well as factors normally regulating accessibility of amine to intraneuronal MAO.
Citations in the library
Cited by 10
- Psychedelics: Where we are now, why we got here, what we must do Neuropharmacology February 21, 2018
- The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen Psychopharmacology February 19, 2010
- The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain Brain Research December 1, 2002
- Editors' Introduction: Hallucinogens at the Turn of the Century Journal of Psychoactive Drugs December 1, 1998
- Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats Journal of Psychopharmacology November 1, 2019
and 5 more in the library
Cites 8
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- On the Use and Abuse of LSD Archives of General Psychiatry March 1, 1968
- Serotonin-Sensitive Adenylate Cyclase in Neural Tissue and Its Similarity to the Serotonin Receptor: A Possible Site of Action of Lysergic Acid Diethylamide Proceedings of the National Academy of Sciences March 1, 1974
- Stereospecific receptor sites for d-lysergic acid diethylamide in rat brain: effects of neurotransmitters, amine antagonists, and other psychotropic drugs. Molecular Pharmacology July 1, 1976
- Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors Psychopharmacology 1977
and 3 more in the library